It is easy to picture cryonics as a finished recipe: cool, store, wait. It is not. It is an active research field, and the distance between a preservation done in 1970 and one done today is enormous. That progress is the quiet reason for optimism, because the quality of a preservation is not fixed. Every improvement in how faithfully a brain's structure is held directly raises the odds that a future medicine has something intact to work with. This article is about how the field actually advances, and who is doing the work.
A field, not a single technique
The decisive shift was the move from crude freezing to vitrification, the glass-like state-forming approach proposed by cryobiologist Greg Fahy in 1984 and adopted as the standard for human cases around the turn of the millennium. Vitrification did not arrive finished either. The cryoprotectant solutions that make it possible have gone through generations of refinement, each one trading a little less toxicity for a little more protection, and that refinement is ongoing. A field that keeps improving its core method is not a dead end. It is a moving target pointed in the right direction.
How the research is organized
Modern biostasis research is a division of labor rather than one monolith. Tomorrow.bio was founded in 2019. The focus here is medical and engineering: the standby and stabilization protocols and the perfusion hardware. It also covers the logistics of reaching a patient fast enough to win the race against cellular decay. The European Biostasis Foundation (EBF) is the Swiss non-profit that operates long-term storage from its facility in Rafz. Its research is applied and translational. That includes Intermediate Temperature Storage, which holds patients below the glass transition but warmer than liquid nitrogen to reduce fracturing. Newer efforts fund basic-science moonshots. The point of the split is that "cryonics research" spans everything from an ambulance protocol to fundamental cryobiology, and no single group does all of it.
The people pushing the science
Much of the deep work happens at dedicated labs. Advanced Neural Biosciences (ANB), founded in 2008 by Aschwin de Wolf and Chana Phaedra, is one of the few institutes devoted specifically to the cryobiology of the brain. Its stated aim is the ice-free preservation of the mammalian brain without loss of ultrastructural detail, by developing vitrification solutions with negligible toxicity, low viscosity, and good penetration across the blood-brain barrier. ANB studies exactly how cerebral ischemia damages tissue. It also works on the "no-reflow" problem, where blood will not re-perfuse tissue after a delay. This is the kind of unglamorous research that decides whether a real-world preservation is good or poor.
The field also gathers in the open. The annual Biostasis conference has run since 2020. It brings together the people whose names recur throughout this Codex. Greg Fahy works on brain cryopreservation. Aschwin de Wolf works on neural cryobiology. Ramon Risco works on organ cryopreservation and nanowarming. Eric Vogt of International Cryomedicine Experts works on real-world standby protocols across more than a hundred cases. Researchers like Joao Pedro de Magalhaes work on the biology of aging. This matters for a simple reason: a field that argues in public, at conferences and in journals, is behaving like science, not like a faith.
Making quality measurable
Perhaps the most important recent shift is the move to measure preservation quality rather than just assert it. The field has begun proposing standardized metrics. Two examples: a Standardized Measure of Ischemic Exposure (S-MIX), and initial cooling rate normalized to patient weight. Metrics like these let one case be compared to another. Protocols can then be judged by evidence. S-MIX converts a case's whole temperature and circulation history, the warm ischemia before stabilization and the cold ischemia during cooling alike, into one number: the equivalent minutes of ischemia at normal body temperature. You cannot improve what you cannot measure, and the arrival of real quality metrics is a sign of a field maturing out of anecdote.
It also reframes the honest variability between cases: preservation done with a standby team present and minimal ischemia is measurably better than a delayed, far-from-help case. Naming and measuring that gap is how it gets closed over time.
Why this is the optimistic part
None of this changes the honest baseline that revival is currently not possible. What it changes is the trajectory. The reason to expect the odds to improve is not faith in a single breakthrough. Dozens of researchers, across several organizations and disciplines, are steadily shrinking the damage. They are improving the solutions and making the whole process measurable. The published literature bears this out, and the candidate routes it feeds into are laid out in how we might achieve revival.
Cryonics is not a finished technology waiting passively for the future. It is a research field actively making itself better. A person preserved today benefits from a method that is measurably better than it was a decade ago. That method is worse than it will be a decade from now.